Cargando…

Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis

Clinical efficacy and adverse reactions of pemetrexed combined with stereotactic gamma-ray radiotherapy in the treatment of patients with lung adenocarcinoma brain metastasis in The First People's Hospital of Yunnan Province were evaluated. A total of 67 patients with lung adenocarcinoma brain...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guoqiao, Zeng, Rong, Wang, Kai, A, Yinzhuoyang, Li, Linhai, Gong, Kunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365961/
https://www.ncbi.nlm.nih.gov/pubmed/30854063
http://dx.doi.org/10.3892/ol.2019.9894
_version_ 1783393512874573824
author Zhang, Guoqiao
Zeng, Rong
Wang, Kai
A, Yinzhuoyang
Li, Linhai
Gong, Kunmei
author_facet Zhang, Guoqiao
Zeng, Rong
Wang, Kai
A, Yinzhuoyang
Li, Linhai
Gong, Kunmei
author_sort Zhang, Guoqiao
collection PubMed
description Clinical efficacy and adverse reactions of pemetrexed combined with stereotactic gamma-ray radiotherapy in the treatment of patients with lung adenocarcinoma brain metastasis in The First People's Hospital of Yunnan Province were evaluated. A total of 67 patients with lung adenocarcinoma brain metastasis in experimental group were treated with simple pemetrexed chemotherapy, and then with radiotherapy, followed by pemetrexed chemotherapy. Their treatment results were compared with those of 53 patients treated with simple gamma knife in control group. The results were analyzed by comparing the clinical efficacy, side reactions, serum level changes, and survival between the two groups. Among 67 patients in the experimental group, there were 16 cases of complete response (CR), 39 cases of partial response (PR), 7 cases of stable disease (SD) and 5 cases of progressive disease (PD), with an effective rate of 82.09% (55/67) and a tumor local control rate of 92.54% (62/67). Among 53 patients in the control group, there were 13 cases of CR, 20 cases of PR, 9 cases of SD and 11 cases of PD, with an effective rate of 62.26% (33/53) and a tumor local control rate of 79.25% (42/53). There were statistically significant differences in the effective rate and local control rate between the two groups (P<0.05). The 6-, 12- and 24-month survival rates in experimental group were higher than those in control group (P<0.05). The main adverse reactions after pemetrexed combined with radiotherapy were lower than those after simple radiotherapy (P<0.05). The expression levels of the tumor markers carcinoembryonic antigen (CEA) and cytokeratin fragment antigen 21-1 (CYFRA21-1) in the two groups of patients after treatment were lower than those before treatment (P<0.05). After treatment, the expression levels of serum CEA and CYFRA21-1 in the experimental group were significantly lower than those in the control group (P<0.05). Pemetrexed combined with radiotherapy in the treatment of lung adenocarcinoma brain metastasis is more effective than simple radiotherapy, with lighter adverse reactions, worthy of clinical application and promotion.
format Online
Article
Text
id pubmed-6365961
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-63659612019-03-08 Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis Zhang, Guoqiao Zeng, Rong Wang, Kai A, Yinzhuoyang Li, Linhai Gong, Kunmei Oncol Lett Articles Clinical efficacy and adverse reactions of pemetrexed combined with stereotactic gamma-ray radiotherapy in the treatment of patients with lung adenocarcinoma brain metastasis in The First People's Hospital of Yunnan Province were evaluated. A total of 67 patients with lung adenocarcinoma brain metastasis in experimental group were treated with simple pemetrexed chemotherapy, and then with radiotherapy, followed by pemetrexed chemotherapy. Their treatment results were compared with those of 53 patients treated with simple gamma knife in control group. The results were analyzed by comparing the clinical efficacy, side reactions, serum level changes, and survival between the two groups. Among 67 patients in the experimental group, there were 16 cases of complete response (CR), 39 cases of partial response (PR), 7 cases of stable disease (SD) and 5 cases of progressive disease (PD), with an effective rate of 82.09% (55/67) and a tumor local control rate of 92.54% (62/67). Among 53 patients in the control group, there were 13 cases of CR, 20 cases of PR, 9 cases of SD and 11 cases of PD, with an effective rate of 62.26% (33/53) and a tumor local control rate of 79.25% (42/53). There were statistically significant differences in the effective rate and local control rate between the two groups (P<0.05). The 6-, 12- and 24-month survival rates in experimental group were higher than those in control group (P<0.05). The main adverse reactions after pemetrexed combined with radiotherapy were lower than those after simple radiotherapy (P<0.05). The expression levels of the tumor markers carcinoembryonic antigen (CEA) and cytokeratin fragment antigen 21-1 (CYFRA21-1) in the two groups of patients after treatment were lower than those before treatment (P<0.05). After treatment, the expression levels of serum CEA and CYFRA21-1 in the experimental group were significantly lower than those in the control group (P<0.05). Pemetrexed combined with radiotherapy in the treatment of lung adenocarcinoma brain metastasis is more effective than simple radiotherapy, with lighter adverse reactions, worthy of clinical application and promotion. D.A. Spandidos 2019-03 2019-01-04 /pmc/articles/PMC6365961/ /pubmed/30854063 http://dx.doi.org/10.3892/ol.2019.9894 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhang, Guoqiao
Zeng, Rong
Wang, Kai
A, Yinzhuoyang
Li, Linhai
Gong, Kunmei
Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
title Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
title_full Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
title_fullStr Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
title_full_unstemmed Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
title_short Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
title_sort clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365961/
https://www.ncbi.nlm.nih.gov/pubmed/30854063
http://dx.doi.org/10.3892/ol.2019.9894
work_keys_str_mv AT zhangguoqiao clinicalefficacyandsafetyevaluationofpemetrexedcombinedwithradiotherapyintreatmentofpatientswithlungadenocarcinomabrainmetastasis
AT zengrong clinicalefficacyandsafetyevaluationofpemetrexedcombinedwithradiotherapyintreatmentofpatientswithlungadenocarcinomabrainmetastasis
AT wangkai clinicalefficacyandsafetyevaluationofpemetrexedcombinedwithradiotherapyintreatmentofpatientswithlungadenocarcinomabrainmetastasis
AT ayinzhuoyang clinicalefficacyandsafetyevaluationofpemetrexedcombinedwithradiotherapyintreatmentofpatientswithlungadenocarcinomabrainmetastasis
AT lilinhai clinicalefficacyandsafetyevaluationofpemetrexedcombinedwithradiotherapyintreatmentofpatientswithlungadenocarcinomabrainmetastasis
AT gongkunmei clinicalefficacyandsafetyevaluationofpemetrexedcombinedwithradiotherapyintreatmentofpatientswithlungadenocarcinomabrainmetastasis